Clinical Trial Update: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with deletion 5q or monosomy 5; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Nordic MDS Group | Conditions: MDS, AML | Phase 2 | Status: COMPLETED